Executive Functions in Tobacco Dependence: Importance of Inhibitory Capacities

PLoS One. 2016 Mar 8;11(3):e0150940. doi: 10.1371/journal.pone.0150940. eCollection 2016.

Abstract

Background: Executive functions are linked to tobacco dependence and craving. In this cross-sectional study, we assessed the impact of three executive functions: updating, inhibition and shifting processes on tobacco craving and dependence.

Method: 134 tobacco consumers were included in this study: 81 moderately (Fagerström score <7) and 53 heavily dependent (Fagerström score >7). Dependence was assessed with the Fagerström test and craving with the tobacco craving questionnaire (TCQ 12). We used the Stroop test and the Hayling test to measure inhibition, the Trail Making Test to measure shifting processes and the n-back test to measure updating processes. A multivariate logistic model was used to assess which variables explained best the level of nicotine dependence.

Results: Inhibition (p = 0.002) and updating (p = 0.014) processes, but not shifting processes, were associated with higher tobacco dependence. Inhibition capacity had a significant effect on the nicotine dependence level independently of age, education, time since last cigarette, intellectual quotient, craving, updating and shifting process.

Conclusions: Nicotine dependence level seems better explained by inhibition capacities than by craving and updating effects. The capacity to inhibit our behaviours is a good predictor of the severity of tobacco dependence. Our results suggest a prefrontal cortex dysfunction affecting the inhibitory capacities of heavy tobacco dependent smokers. Further studies are needed to investigate the application of these findings in the treatment of tobacco dependence.

Trial registration: ClinicalTrials.gov NCT01554436.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Comorbidity
  • Craving
  • Cross-Sectional Studies
  • Executive Function*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Risk Factors
  • Surveys and Questionnaires
  • Tobacco Use Disorder / epidemiology
  • Tobacco Use Disorder / physiopathology*
  • Tobacco Use Disorder / psychology*

Associated data

  • ClinicalTrials.gov/NCT01554436

Grants and funding

This study received financial support from CHU Montpellier (PHRC UF 8269, clinical trial.gouv NCT01554436). CHU Montpellier had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.